Skip to main content
Top
Published in: Neurological Sciences 12/2015

01-12-2015 | Original Article

Independent effect of fatigue on health-related quality of life in patients with idiopathic Parkinson’s disease

Authors: Vasfiye Burcu Dogan, Ayhan Koksal, Ayten Dirican, Sevim Baybas, Ahmet Dirican, Gulsum Buse Dogan

Published in: Neurological Sciences | Issue 12/2015

Login to get access

Abstract

Nonmotor symptoms (NMS) of idiopathic Parkinson’s disease (IPD), specifically fatigue, depression and sleep disturbances, are important contributors for worse quality of life and poor patient outcomes. The aim of this research is to determine the relationship between fatigue and other NMS and the independent effect of fatigue on health-related quality of life (HRQoL) in patients with IPD. 86 IPD patients and 85 healthy individuals were included in our study. Participants were evaluated by their answers to the Beck Depression Inventory, Fatigue Severity Scale, Epworth Sleepiness Scale and Parkinson’s Disease Questionnaire-39. Hoehn–Yahr stage, disease duration, medications and demographical characteristics were also noted. ROC analysis was used to determine the cutoff point for HRQoL. Nonparametric Spearman correlation analysis was used for determining the relationship between variables. Independent factors which affect HRQoL were detected by multiple forward stepwise logistic regression analysis. NMS were associated with each other and with HRQoL when they act concomitantly (p < 0.001). Of these three frequent NMS, depression (p < 0.05) and fatigue (p < 0.001) had independent worsening effect on HRQoL, whereas sleep disturbances did not (p > 0.05). The stage of IPD and levodopa–entacapone treatment had independent effects on HRQoL too (p < 0.05). Fatigue was found as the most important factor which affects HRQoL among all investigated NMS. So, it is important to ask about fatigue in routine controls of IPD patients and try to treat it for improving life quality.
Literature
1.
go back to reference George S, Rey NL, Reichenbach N, Steiner JA, Brundin P (2013) α-Synuclein: the long distance runner. Brain Pathol 3(3):350–357CrossRef George S, Rey NL, Reichenbach N, Steiner JA, Brundin P (2013) α-Synuclein: the long distance runner. Brain Pathol 3(3):350–357CrossRef
2.
3.
go back to reference Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG (2014) Relationship between the MDS-UPDRS domains and the health related quality of life of Parkinson’s disease patients. Eur J Neurol 21(3):519–524CrossRefPubMed Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG (2014) Relationship between the MDS-UPDRS domains and the health related quality of life of Parkinson’s disease patients. Eur J Neurol 21(3):519–524CrossRefPubMed
4.
5.
go back to reference Greim B, Benecke R, Zettl UK (2007) Qualitative and quantitative assessment of fatigue in multiple sclerosis (MS). J Neurol 254(2):II58–II64PubMed Greim B, Benecke R, Zettl UK (2007) Qualitative and quantitative assessment of fatigue in multiple sclerosis (MS). J Neurol 254(2):II58–II64PubMed
6.
go back to reference Pfeiffer RF (2007) Non-motor parkinsonism. Parkinsonism Relat Disord 13(3):211–220CrossRef Pfeiffer RF (2007) Non-motor parkinsonism. Parkinsonism Relat Disord 13(3):211–220CrossRef
7.
go back to reference Mendonça DA, Menezes K, Jog MS (2007) Methylphenidate improves fatigue scores in Parkinson’s disease: a randomized controlled trial. Mov Disord 22(14):2070–2076CrossRefPubMed Mendonça DA, Menezes K, Jog MS (2007) Methylphenidate improves fatigue scores in Parkinson’s disease: a randomized controlled trial. Mov Disord 22(14):2070–2076CrossRefPubMed
8.
go back to reference Datieva VK, Rosinskaia AV, Levin OS (2013) The use of melatonin in the treatment of chronic fatigue syndrome and circadian rhythm disorders in Parkinson’s disease. Zh Nevrol Psikhiatr Im S S Korsakova 113(7 Pt 2):77–81PubMed Datieva VK, Rosinskaia AV, Levin OS (2013) The use of melatonin in the treatment of chronic fatigue syndrome and circadian rhythm disorders in Parkinson’s disease. Zh Nevrol Psikhiatr Im S S Korsakova 113(7 Pt 2):77–81PubMed
9.
go back to reference Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–1123CrossRefPubMed Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–1123CrossRefPubMed
10.
go back to reference Izci B, Ardic S, Fırat H, Sahin A, Altınors M, Karacak I (2008) Reliability and validity studies of the Turkish version of the Epworth Sleepiness Scale. Sleep Breath 12:161–168CrossRefPubMed Izci B, Ardic S, Fırat H, Sahin A, Altınors M, Karacak I (2008) Reliability and validity studies of the Turkish version of the Epworth Sleepiness Scale. Sleep Breath 12:161–168CrossRefPubMed
11.
go back to reference Beck Aaron T (1998) Psychometric properties of the Beck Depression Inventory: twenty five years of evaluation. Clin Psychol Rev 8(1):77–100CrossRef Beck Aaron T (1998) Psychometric properties of the Beck Depression Inventory: twenty five years of evaluation. Clin Psychol Rev 8(1):77–100CrossRef
12.
go back to reference The Global Parkinson’s Disease Survey (GPDS) Steering Committee (2002) Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 17(1):60–67CrossRef The Global Parkinson’s Disease Survey (GPDS) Steering Committee (2002) Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 17(1):60–67CrossRef
13.
go back to reference Peto V, Jenkinson C, Fitzpatrick R et al (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4:241–248CrossRefPubMed Peto V, Jenkinson C, Fitzpatrick R et al (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4:241–248CrossRefPubMed
14.
go back to reference Shulman LM, Taback RL, Bean J, Weiner WJ (2001) Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 16(3):507–510CrossRefPubMed Shulman LM, Taback RL, Bean J, Weiner WJ (2001) Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 16(3):507–510CrossRefPubMed
15.
go back to reference Okuma Y, Kamei S, Morita A, Yoshii F, Yamamoto T, Hashimoto S, Utsumi H, Hatano T, Hattori N, Matsumura M, Takahashi K, Nogawa S, Watanabe Y, Miyamoto M, Hirata K (2009) Fatigue in Japanese patients with Parkinson’s disease: a study using Parkinson fatigue scale. Mov Disord 24(13):1977–1983CrossRefPubMed Okuma Y, Kamei S, Morita A, Yoshii F, Yamamoto T, Hashimoto S, Utsumi H, Hatano T, Hattori N, Matsumura M, Takahashi K, Nogawa S, Watanabe Y, Miyamoto M, Hirata K (2009) Fatigue in Japanese patients with Parkinson’s disease: a study using Parkinson fatigue scale. Mov Disord 24(13):1977–1983CrossRefPubMed
16.
go back to reference Kang SY, Ma HI, Lim YM, Hwang SH, Kim YJ (2013) Fatigue in drug-naive Parkinson’s disease. Eur Neurol 70(1–2):59–64CrossRefPubMed Kang SY, Ma HI, Lim YM, Hwang SH, Kim YJ (2013) Fatigue in drug-naive Parkinson’s disease. Eur Neurol 70(1–2):59–64CrossRefPubMed
17.
18.
go back to reference Stocchi F, Abbruzzese G, Ceravolo R, Cortelli P, D’Amelio M, De Pandis MF, Fabbrini G, Pacchetti C, Pezzoli G, Tessitore A, Canesi M, Iannacone C, Zappia M, FORTE Study Group (2014) Prevalence of fatigue in Parkinson’s disease and it’s clinical correlates. Neurology 83(3):215–220CrossRefPubMed Stocchi F, Abbruzzese G, Ceravolo R, Cortelli P, D’Amelio M, De Pandis MF, Fabbrini G, Pacchetti C, Pezzoli G, Tessitore A, Canesi M, Iannacone C, Zappia M, FORTE Study Group (2014) Prevalence of fatigue in Parkinson’s disease and it’s clinical correlates. Neurology 83(3):215–220CrossRefPubMed
19.
go back to reference Oved D, Ziv I, Treves TA, Paleacu D, Melamed E, Djaldetti R (2006) Effect of dopamine agonists on fatigue and somnolence in Parkinson’s disease. Mov Disord 21(8):1257–1261CrossRefPubMed Oved D, Ziv I, Treves TA, Paleacu D, Melamed E, Djaldetti R (2006) Effect of dopamine agonists on fatigue and somnolence in Parkinson’s disease. Mov Disord 21(8):1257–1261CrossRefPubMed
20.
go back to reference Karlsen K, Larsen JP, Tandberg E, Jorgessen K (1999) Fatigue in patients with Parkinson’s disease. Mov Disord 14(2):237–241CrossRefPubMed Karlsen K, Larsen JP, Tandberg E, Jorgessen K (1999) Fatigue in patients with Parkinson’s disease. Mov Disord 14(2):237–241CrossRefPubMed
21.
go back to reference Alves G, Wentzel-Larsen T, Larsen JP (2004) Is fatigue an independent and persistant symptom in patients with Parkinson’s disease? Neurology 63(10):1908–1911CrossRefPubMed Alves G, Wentzel-Larsen T, Larsen JP (2004) Is fatigue an independent and persistant symptom in patients with Parkinson’s disease? Neurology 63(10):1908–1911CrossRefPubMed
22.
go back to reference Lou JS, Dimitrova DM, Park BS, Johnson SC, Eaton R, Arnold G, Nutt JG (2009) Using modafinil to treat fatigue in Parkinson’s disease: a double blind, placebo-controlled pilot study. Clin Neuropharmacol 32(6):305–310CrossRefPubMed Lou JS, Dimitrova DM, Park BS, Johnson SC, Eaton R, Arnold G, Nutt JG (2009) Using modafinil to treat fatigue in Parkinson’s disease: a double blind, placebo-controlled pilot study. Clin Neuropharmacol 32(6):305–310CrossRefPubMed
23.
go back to reference Elbers RG, van Wegen EE, Verhoef J, Kwakkel G (2014) Impact of fatigue on health-related quality of life in patients with Parkinson’s disease: a prospective study. Clin Rehabil. 28(3):300–311CrossRefPubMed Elbers RG, van Wegen EE, Verhoef J, Kwakkel G (2014) Impact of fatigue on health-related quality of life in patients with Parkinson’s disease: a prospective study. Clin Rehabil. 28(3):300–311CrossRefPubMed
24.
go back to reference Song W, Guo X, Chen K, Chen X, Cao B, Wei Q, Huang R, Zhao B, Wu Y, Shang HF (2014) The impact of nonmotor symptoms on the health related quality of life of Parkinson’s disease patients from Southwest China. Parkinsonism Relat Disord 20(2):149–152CrossRefPubMed Song W, Guo X, Chen K, Chen X, Cao B, Wei Q, Huang R, Zhao B, Wu Y, Shang HF (2014) The impact of nonmotor symptoms on the health related quality of life of Parkinson’s disease patients from Southwest China. Parkinsonism Relat Disord 20(2):149–152CrossRefPubMed
25.
go back to reference Mao CJ, Cao LD, Tang Q, Liu CF (2013) Observations on fatigue, depression and quality of life in patients with Parkinson’s disease. Zhonghua Nei Za Zhi 52(3):200–202 Mao CJ, Cao LD, Tang Q, Liu CF (2013) Observations on fatigue, depression and quality of life in patients with Parkinson’s disease. Zhonghua Nei Za Zhi 52(3):200–202
Metadata
Title
Independent effect of fatigue on health-related quality of life in patients with idiopathic Parkinson’s disease
Authors
Vasfiye Burcu Dogan
Ayhan Koksal
Ayten Dirican
Sevim Baybas
Ahmet Dirican
Gulsum Buse Dogan
Publication date
01-12-2015
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 12/2015
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-015-2340-9

Other articles of this Issue 12/2015

Neurological Sciences 12/2015 Go to the issue